Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma

Medical Science Monitor

Volumn 19, Issue 1, 2013, Pages 742-750

  Taura, Naota ^a   Ichikawa, Tatsuki ^a   Miyaaki, Hisamitsu ^a   Ozawa, Eisuke ^b   Tsutsumi, Takuya ^c   Tsuruta, Shotaro ^d   Kato, Yuji ^e   Goto, Takashi ^f   Kinoshita, Noboru ^g   Fukushima, Masanori ^h   Kato, Hiroyuki ⁱ   Ohata, Kazuyuki ^j   Ohba, Kazuo ^k   Masuda, Junichi ^l   Hamasaki, Keisuke ^m   Yatsuhashi, Hiroshi ⁿ   Nakao, Kazuhiko ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b Sasebo Shiritsu Sogo Hospital   (Japan)

^c Nagasaki Municipal Hospital   (Japan)

^d JAPANESE RED CROSS NAGASAKI GENBAKU HOSPITAL   (Japan)

^e OITA PREFECTURAL HOSPITAL   (Japan)

^f Japan Labour Health and Welfare Organization   (Japan)

^g SASEBO CHUO HOSPITAL   (Japan)

^h Goto Central Hospital   (Japan)

ⁱ National Saga Hospital   (Japan)

^j Kouseikai Hospital   (Japan)

^k Isahaya Health Insurance General Hospital   (Japan)

^l Department of Gastroenterology and Hepatology   (Japan)

^m Caritas Clinic   (Japan)

ⁿ NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

more..

Author keywords

AFP; DCP; HCC

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DECARBOXYPROTHROMBIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER STAGING; CANCER SURVIVAL; CHRONIC HEPATITIS; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PROTHROMBIN TIME; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE COUNT;

AGE FACTORS; ALCOHOL DRINKING; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; BODY MASS INDEX; CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INCIDENCE; JAPAN; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LOGISTIC MODELS; PROTEIN PRECURSORS; PROTHROMBIN; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883672507     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.889361     Document Type: Article

References (48)

1. El-Serag HB, Mason AC: Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med, 2000; 160: 3227-30
2. el-Serag HB: Epidemiology of hepatocellular carcinoma. Clin Liver Dis, 2001; 5: 87-107, vi
3. El-Serag HB, Hampel H, Yeh C et al: Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology, 2002; 36: 1439-45
4. El-Serag HB: Hepatocellular carcinoma and hepatitis C in the United States. Hepatology, 2002; 36: S74-83
5. El-Serag HB: Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol, 2002; 35: S72-78
6. Hassan MM, Frome A, Patt YZ et al: Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol, 2002; 35: 266-69
7. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007; 132: 2557-76
8. Kiyosawa K, Tanaka E: Characteristics of hepatocellular carcinoma in Japan. Oncology, 2002; 62: 5-7
9. McGlynn KA, Tsao L, Hsing AW et al: International trends and patterns of primary liver cancer. Int J Cancer, 2001; 94: 290-96
10. Bosch FX, Ribes J, Diaz M et al: Primary liver cancer: worldwide incidence and trends. Gastroenterology, 2004; 127: S5-S16
11. Hamasaki K, Nakata K, Tsutsumi T et al: Changes in the prevalence of hepatitis B and C infection in patients with hepatocellular carcinoma in the Nagasaki Prefecture, Japan. J Med Virol, 1993; 40: 146-49
12. Kato Y, Nakata K, Omagari K et al: Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer, 1994; 74: 2234-38
13. Shiratori Y, Shiina S, Imamura M et al: Characteristic difference of hepatocellular carcinoma between hepatitis B-and C-viral infection in Japan. Hepatology, 1995; 22: 1027-33
14. Shiratori Y, Shiina S, Zhang PY et al: Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan? Cancer, 1997; 80: 2060-67
15. Taura N, Yatsuhashi H, Nakao K et al: Long-term trends of the incidence of hepatocellular carcinoma in the Nagasaki prefecture, Japan. Oncol Rep, 2009; 21: 223-27
16. Taura N, Fukushima N, Yastuhashi H et al: The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. Med Sci Monit, 2011; 17(2): PH7-11
17. Omata M, Tateishi R, Yoshida H et al: Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology, 2004; 127: S159-66
18. Calvet X, Bruix J, Gines P et al: Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology, 1990; 12: 753-60
19. Schafer DF, Sorrell MF: Hepatocellular carcinoma. Lancet, 1999; 353: 1253-57
20. Akriviadis EA, Llovet JM, Efremidis SC et al: Hepatocellular carcinoma. Br J Surg, 1998; 85: 1319-31
21. Ngan H, Lai CL, Fan ST et al: Transcatheter arterial chemoembolization in inoperable hepatocellular carcinoma: four-year follow-up. J Vasc Interv Radiol, 1996; 7: 419-25
22. Oka H, Kurioka N, Kim K et al: Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology, 1990; 12: 680-87
23. Lai CL, Lau JY, Wu PC et al: Subclinical hepatocellular carcinoma in Hong Kong Chinese. Oncology, 1992; 49: 347-53
24. Colombo M, de Franchis R, Del Ninno E et al: Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med, 1991; 325: 675-80
25. Pateron D, Ganne N, Trinchet JC et al: Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol, 1994; 20: 65-71
26. Akahoshi H, Taura N, Ichikawa T et al: Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma. Oncol Rep, 2010; 23: 1317-23
27. Wada I, Hara T, Kajihara S et al: Population-based study of hepatitis C virus infection and hepatocellular carcinoma in western Japan. Hepatol Res, 2002; 23: 18-24
28. Dohmen K, Shirahama M, Onohara S et al: Differences in survival based on the type of follow-up for the detection of hepatocellular carcinoma: an analysis of 547 patients. Hepatol Res, 2000; 18: 110-21
29. Okuda H, Nakanishi T, Takatsu K et al: Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alphafetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol, 2001; 16: 1290-96
30. Rodriguez-Diaz JL, Rosas-Camargo V, Vega-Vega O et al: Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term followup study. Clin Oncol (R Coll Radiol), 2007; 19: 197-203
31. Bruix J, Sherman M: Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology, 2005; 42: 1208-36
32. Tsukuma H, Hiyama T, Tanaka S et al: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med, 1993; 328: 1797-801
33. Oka H, Tamori A, Kuroki T et al: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology, 1994; 19: 61-66
34. Ganne-Carrie N, Chastang C, Chapel F et al: Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology, 1996; 23: 1112-18
35. Sangiovanni A, Colombo E, Radaelli F et al: Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients. Am J Gastroenterol, 2001; 96: 1575-80
36. Tateyama M, Yatsuhashi H, Taura N et al: Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol, 2011; 46: 92-100
37. Weitz IC, Liebman HA: Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology, 1993; 18: 990-97
38. Kasahara A, Hayashi N, Fusamoto H et al: Clinical evaluation of plasma desgamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci, 1993; 38: 2170-76
39. Takikawa Y, Suzuki K, Yamazaki K et al: Plasma abnormal prothrombin (PIVKA-II): a new and reliable marker for the detection of hepatocellular carcinoma. J Gastroenterol Hepatol, 1992; 7: 1-6
40. Grazi GL, Mazziotti A, Legnani C et al: The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg, 1995; 1: 249-55
41. Marrero JA, Su GL, Wei W et al: Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology, 2003; 37: 1114-21
42. Malaguarnera G, Giordano M, Paladina I et al: Serum markers of hepatocellular carcinoma. Dig Dis Sci, 2010; 55: 2744-55
43. Nakagawa T, Seki T, Shiro T et al: Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int J Oncol, 1999; 14: 281-86
44. Tameda M, Shiraki K, Sugimoto K et al: Des-gamma-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma. Cancer Sci, 2013; 104: 725-31
45. Toyoda H, Kumada T, Osaki Y et al: Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report. Cancer Sci, 2012; 103: 921-25
46. Lok AS, Sterling RK, Everhart JE et al: Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology, 2010; 138: 493-502
47. Okuda H, Obata H, Nakanishi T et al: Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J Hepatol, 1987; 4: 357-63
48. Beale G, Chattopadhyay D, Gray J et al: AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer, 2008; 8: 200